Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Tae Min Kim, Jing-Zhou Hou, Sameh Gaballa, Ranjit Nair, Dai Maruyama, Koji Izutsu, Sumana Devata, Dok Hyun Yoon, Won-Seog Kim, Yazeed Sawalha, Ryan Jacobs, Eliza Hawkes, Ming-Chung Wang, Constantine Tam, Don Stevens, Hisayuki Yokoyama, Jin Seok Kim, Matthew Matasar, Aravind Ramakrishnan, Denise Brennan, David Sermer, Robin Lesley, Xu (Sue) Zhu, Mihail Obrocea, Seok-Goo Cho
Institutions: Seoul National University Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Moffitt Cancer Center, The University of Texas MD Anderson Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, National Cancer Centre Japan, Medical College of Wisconsin, Asan Medical Center, University of Ulsan, Samsung Medical Center, Sungkyunkwan University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Levine Cancer Institute, Austin Health, Kaohsiung Chang Gung Memorial Hospital, The Alfred Hospital, Monash University, Norton Healthcare, Yamagata University, Yonsei University, Severance Hospital, Rutgers Cancer Institute, St David's Medical Center, AstraZeneca (United States), The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417005217